Skip to main content

Table 3 Prescription patterns of concomitant MTX, LFN, SSZ, and PDN with the first TNF antagonist

From: Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Current treatment with synthetic DMARDs plus the first TNF antagonist First TNF antagonist monotherapy First TNF antagonist plus one csDMARD First TNF antagonist plus two or more csDMARDs Total P*
  n % n % n % n %  
  234 21 766 67 136 12 1.136 100  
None (n, %) 172 73        
PDN (n, %) 62 26 336 44 115 84 513 45 0.0001
MTX (n, %)    364 47      < 0.0001
MTX + PDN (n, %)    189 25      < 0.0001
LFN + PDN (n, %)    129 17      < 0.0001
LFN (n, %)    57 7      < 0.0001
SSZ + PDN (n, %)    9 1      < 0.0001
SSZ (n, %)    5 0.6      < 0.0001
Combinations (n, %)          < 0.0001
 MTX + LFN + PDN      66 48   
 MTX + SSZ + PDN      24 17   
 MTX + SSZ      12 9   
 LFN + CLQ + PDN      8 6   
 MTX + SSZ + HCLQ + PDN      5 4   
 MTX + LFN      4 3   
 Others      17 13   
NSAIDs (n, %) 201 86 673 88 127 93 1.013 88 0.09
  Mean SD Mean SD Mean SD Mean SD  
Current PDN dose, mg/day (mean ± SD) 10.7 ±5.6 9.6 ±6.7 10.0 ±7.5 9.8 ±6.6 0.002
Current MTX dose, mg/week (mean ± SD) 0 0 15.3 ±4.8 16.0 4.7 15.5 4.8 0.08
Duration of current treatment with MTX (months) (mean ± SD)    31.0 32.2 21.5 23.6 27.6 28.6 0.0001
Current LFN dose, mg/day (mean ± SD) 0 0 18.8 3.1 15.6 4.9 17.8 4.0 < 0.0001
Duration of current treatment with LFN (months) (mean ± SD)    12.9 19.0 9.4 9.9 12.0 16.5 0.5
Follow up, (years) (mean ± SD) 2.1 1.0 1.8 1.0 1.6 1.1 1.8 1.1 0.0001
  1. csDMARD conventional synthetic disease-modifying antirheumatic drug, DMARD disease-modifying antirheumatic drug, MTX methotrexate, LFN leflunomide, SSZ sulfasalazine, PDN prednisone, NDAID non-steroidal anti-inflammatory drug